Statement of the Italian National Association of Hospital Cardiologists (ANMCO) for the treatment of high blood cholesterol in the secondary prevention of coronary heart disease;Il trattamento dell'ipercolesterolemia in prevenzione secondaria. Statement dell'ANMCO

Giornale Italiano di Cardiologia

Volumn 28, Issue 4, 1998, Pages 409-415

  Marchioli, Roberto ^a   Valagussa, Franco ^b   Vanuzzo, Diego ^c   Giannuzzi, Pantaleo ^d   Pede, Sergio ^e   Schweiger, Carlo ^f  

^a Laboratorio Angela Valenti dei Fattori Genetici e Ambientali di Rischio Trombotico   (Italy)

^b SAN GERARDO HOSPITAL   (Italy)

^c SANTA MARIA DELLA MISERICORDIA UNIVERSITY HOSPITAL   (Italy)

^d IRCCS   (Italy)

^e Ospedale N Melli   (Italy)

^f Regione Piemonte USL 49   (Italy)

Author keywords

Guidelines; Hypercholesterolemia; Ischemic heart disease; Medical therapy

Indexed keywords

ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL PROTOCOL; CORONARY ARTERY DISEASE; CORONARY RISK; HUMAN; HYPERCHOLESTEROLEMIA; TREATMENT PLANNING;

CHOLESTEROL, LDL; CORONARY DISEASE; HUMANS; HYPERCHOLESTEROLEMIA; RISK FACTORS;

EID: 0031895721     PISSN: 00465968     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. LEVINE GN, KEANEY JF, VITA JA: Cholesterol reduction in cardiovascular disease: clinical benefits and possible mechanisms. N Engl J Med 1994; 332: 512-521.
2. LA ROSA JC: Cholesterol lowering as a treatment for established coronary heart disease. Circulation 1992; 85: 1229-1235.
3. EDITORIAL: Is reduction of blood cholesterol effective? Lancet 1984; i: 317-318.
4. ROBERTS WC: Atherosclerotic risk factors. Are there ten or is there only one? Am J Cardiol 1989; 64: 552-554.
5. EDITORIAL: Low cholesterol and increased risk. Lancet 1989; i: 1423-1425.
6. CANNER PL, BERGE KG, WENGER NK, ET AL: Fifteen year mortality in coronary drug project patients. Long-term benefit with niacin. J Am Coll Cardiol 1986; 8: 1245-1255.
7. CONSENSUS CONFERENCE: Lowering blood cholesterol to prevent heart disease. JAMA 1985; 253: 2080-2086.
8. HENRY PD: The cholesterol pessimist (editorial). J Am Coll Cardiol 1988; 12: 818-819.
9. OLIVER MF: Serum cholesterol - the knave of hearts and the joker. Lancet 1981; 2: 1090-1095.
10. OLIVER MF: Why measure cholesterol after myocardial infarction, and when? (editorial). Br Med J 1984; 289: 1641-1642.
11. OLIVER MF: Hypercholesterolaemia and coronary heart disease. An answer (editorial). Br Med J 1984; 288: 423-424.
12. OLIVER MF: Reducing cholesterol does not reduce mortality. J Am Coll Cardiol 1988; 12: 814-817.
13. BRETT AS: Treating hypercholesterolemia. How should practicing physicians interpret the published data for patients? N Engl J Med 1989; 321: 676-880.
14. GARBER AM: Where to draw the line against cholesterol. Ann Intern Med 1989; 111: 625-627.
15. FROOM J, FROOM P: "Prudence" in disease prevention. J Clin Epidemiol 1991; 44: 1127-1130.
16. BRETT AS: Psychologic effects of the diagnosis and treatment of hypercholesterolemia. Lessons from case studies. Am J Med 1991; 91: 642-647.
17. NAYLOR CD: Cholesterol testing in young adults. Prudent or profligate? JAMA 1993; 269: 1426-1427.
18. OLIVER MF: Doubts about preventing coronary heart disease. Multiple interventions in middle aged men may do more harm than good. Br Med J 1992; 304: 393-394.
19. HULLEY SB, NEWMAN TB, GRADY D, GARBER AM, BARON RB, BROWNER WS: Should we be measuring blood cholesterol levels in young adults? JAMA 1993; 269: 1416-1419.
20. ABRAMS FR: The doctor with two heads. The patient versus the costs. N Engl J Med 1993; 328: 975-976.
21. OLIVER MF: National cholesterol policies. Eur Heart J 1993; 14: 581-583.
22. CRIQUI MH: Cholesterol, primary and secondary prevention, and all-cause mortality. Ann Intern Med 1991; 115: 973-976.
23. HULLEY SB, WALSH JMB, NEWMAN TB: Health policy on blood cholesterol. Time to change directions. Circulation 1992; 86: 1026-1029.
24. EDITORIAL: Secondary prevention of coronary disease with lipid-lowering drugs. Lancet 1989; i: 473-474.
25. COLLINS R, KEECH A, PETO R, ET AL: Cholesterol and total mortality, need for larger trials. Br Med J 1992; 304: 1689.
26. COHEN MV, BYRNE MJ, LEVINE B, GUTOWSKI T, ADELSON R: Low rate of treatment of hypercholesterolemia by cardiologists in patients with suspected and proven coronary artery disease. Circulation 1991; 83: 1294-1304.
27. National cholesterol education program expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. Arch Intern Med 1988; 148: 36-69.
28. EUROPEAN ATHEROSCLEROSIS SOCIETY STUDY GROUP: The recognition and management of hyperlipidaemia in adults. A policy statement of the European atherosclerosis society. Eur Heart J 1988; 9: 571-600.
29. CANADIAN CONSENSUS CONFERENCE ON CHOLESTEROL: Final Report. Can Med Assoc J 1988; 139: 1-8.
30. CANADIAN TASK FORCE ON THE PERIODIC HEALTH EXAMINATION: Periodic health examination, 1993 update. II. Lowering the blood total cholesterol level to prevent coronary heart disease. Can Med Assoc J 1993; 148: 521-538.
31. TORONTO WORKING GROUP ON CHOLESTEROL POLICY: Asymptomatic hypercholesterolemia: a clinical policy review. J Clin Epidemiol 1990; 43: 1028-1121.
32. EXPERT PANEL ON POPULATION STRATEGIES FOR BLOOD CHOLESTEROL REDUCTION: Report of the Expert Panel on Population Strategies for Blood Cholesterol Reduction: a statement from the National Cholesterol Program. Circulation 1991; 83: 2154-2232.
33. EXPERT PANEL ON DETECTION, EVALUATION AND TREATMENT OF HIGH BLOOD CHOLESTEROL IN ADULTS: Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA 1993; 269: 3015-3023.
34. EXPERT PANEL ON DETECTION, EVALUATION AND TREATMENT OF HIGH BLOOD CHOLESTEROL IN ADULTS: National Cholesterol Education Program: second report of the Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA 1994; 89: 1329-1445.
35. MARCHIOLI R, DI PASQUALE A, PER I RICERCATORI GISSI-PREVENZIONE: Il quadro di riferimento biochimico, farmacologico, epidemiologico del GISSI-Prevenzione. G Ital Cardiol 1993; 23: 933-964.
36. GRUPPO ITALIANO STUDIO SULLA SOPRAVVIVENZA NELL'INFARTO MIOCARDICO (GISSI): Il protocollo dello studio GISSI-Prevenzione: studio di intervento preventive sulle componenti aterosclerotica e trombotica del rischio post-infarto. G Ital Cardiol 1993; 23: 1053-1061.
37. SCANDINAVIAN SIMVASTATIN SURVIVAL STUDY GROUP: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-1389.
38. SHEPHERD J, COBBE SM, FORD I ET AL, FOR THE WEST OF SCOTLAND CORONARY PREVENTION STUDY GROUP: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333: 1301-1307.
39. SACKS FM, PFEFFER MA, MOYE LA ET AL, FOR THE CHOLESTEROL AND RECURRENT EVENTS TRIAL INVESTIGATORS: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001-1009.
40. MARCHIOLI R, MARFISI RM, CARINCI F, TOGNONI G: Meta-analysis, clinical trials, and transferability of research results into practice: the case of cholesterol-lowering interventions in secondary prevention of coronary heart disease. Arch Intern Med 1996; 156: 1158-1172.
41. LA ROSA JC, PEARSON TA: Cholesterol screening guidelines: consensus, evidence, and departure from common sense. Circulation 1997; 95: 1651-1653.
42. CLEEMAN JI, GRUNDY SM: National cholesterol education program recommendations for cholesterol testing in young adults: a science-based approach. Circulation 1997; 95: 1646-1650.
43. GRUNDY SM, BALADY GJ, CRIQUI MH, ET AL: When to start cholesterol-lowering therapy in patients with coronary heart disease: a statement for healthcare professionals from the American Heart Association Task Force on Risk Reduction. Circulation 1997; 95: 1683-1685.
44. OLIVER MF, PYORALA K, SHEPHERD J: Management of hyperlipidaemia: why, when and how treat. Eur Heart J 1997; 18: 371-375.
45. AVINS AL, BROWNER WS: Lowering risk without towering cholesterol: implications for National Cholesterol Policy. Ann Intern Med 1996; 125: 502-506.
46. TASK FORCE ON RISK REDUCTION: Cholesterol screening in asymptomatic adults: no cause to change. Circulation 1996; 93: 1067-1068.
47. MARCHIOLI R, MARFISI RM: Prevenzione primaria e secondaria della cardiopatia ischemica. Dalla meta-analisi e dalla meta-regressione ai meccanismi biologici: riflessioni per una pratica clinica basata sull'evidenza scientifica. G Ital Cardiol 1998; 28: 434-459.
48. PYORALA K, DE BACKER G, GRAHAM I, POOLE-WILSON PA, WOOD D ON BEHALF OF THE TASK FORCE: Prevention of coronary heart disease in clinical practice. Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Eur Heart J 1994; 15: 1500-1531.
49. MARCHIOLI R, BOMBA E, DI PASQUALE A ET AL, A NOME DEI RICERCATORI GISSI-PREVENZIONE: La Carta del Rischio post-IMA: risultati dei primi 18 mesi di follow-up del GISSI-Prevenzione. G Ital Cardiol 1998; 28: 416-433.
50. MARCHIOLI R, BOMBA E, TOGNONI G: Sheffield risk and treatment table for cholesterol lowering in prevention of coronary heart disease (letter). Lancet 1996; 347: 467-468.
51. MARCHIOLI R, TOGNONI G: Beneficial effects of statins (letter). Lancet 1996; 348: 1542.